浸润性胰腺导管内乳头状黏液性肿瘤的临床特征

回顾性分析40例经外科治疗且术后病理证实的胰腺导管内乳头状黏液性肿瘤(IPMN)患者的临床资料。非浸润性IPMN 26例,浸润性IPMN 14例。浸润性组患者CA19-9>37U/ml 7例,CEA>3.4 ng/ml 6例,肿瘤长径>3 cm 10例,胰管直径>5 mm 11例,增强CT可见壁结节10例,均显著多于非浸润性组的2例,1例,3例,5例,3例,差异均有统计学意义(P值均<0.05)。这些指标均有助于鉴别IPMN的良恶性。     

胰腺导管内乳头状黏液性肿瘤的研究进展

胰腺导管内乳头状黏液性肿瘤（IPMN）是指起源于主胰管或分支胰管内上皮细胞,形成大体可见的乳头状（偶见扁平状）、产黏液的,并伴有不同程度胰管扩张的一类肿瘤,是最常见的胰腺囊性肿瘤.1982年由Ohashi等首先报道,并命名为产黏液胰腺癌;IPMN曾被称为绒毛状腺瘤、乳头状肿瘤、乳头状癌、胰腺黏液导管扩张症及胰腺产黏液性肿瘤等[1].2000年,WHO将胰腺产黏液性肿瘤分成IPMN及黏液性囊性肿瘤（MCN）.根据细胞及组织异型程度,IPMN又被分成非浸润性IPMN（包括低级别、中等级别及高级别异型增生）和浸润性IPMN;根据累及胰管的范围,IPMN又被分为主胰管型（20％）、分支胰管型（40％）及混合型（40％）[2].     

胰腺导管内乳头状黏液性肿瘤诊治进展

胰腺最常见的恶性肿瘤是胰腺导管腺癌,其预后很差。然而,胰腺导管上皮发生的另一类肿瘤,胰腺导管内乳头状黏液性肿瘤(intraductal papillary mucinous tumors,IPMT) 却有着较好的预后,以前临床及病理医师对其尚不熟悉,直至近几年才逐渐被认识。Kimura等曾以以下特点作了报道:(1)胰腺导管内大量的黏液产生和潴留;(2)乏特乳头部开口由于黏液流过而扩大;(3)主要在主胰管内发展和播散;     

胰腺导管内乳头状黏液性肿瘤的研究进展

胰腺导管内乳头状黏液性肿瘤（IPMNs）是一类以胰腺导管上皮乳头样增生和分泌大量黏液为特点的一,类肿瘤,大量黏液堵塞主胰管或分支胰管并使之扩张。近年对IPMNs的流行病学、病理特征与肿瘤基因表达、诊断处理原则方面均有了新的认识。本文就IPMN8的研究进展作一综述。     

胰管内乳头状黏液瘤的临床研究

目的 通过探讨胰管内乳头状黏液瘤（IPMT）的临床、逆行胰胆管造影（ERCP）表现及病理特征,提高对IPMT的认识。方法 对9例IPMT患者的临床、影像学表现及病理资料作回顾性分析。结果 9例中男女之比为2：1,年龄为37-76岁,平均68.4岁。上腹痛为最常见症状。肿瘤主要位于胰头部。ERCP可见十二指肠乳头肿大开口扩大,见大量黏液流出及主胰管扩张。病理表现多样性,可表现为腺瘤和腺癌。结论 IMPT是胰腺肿瘤的一种,其预后较一般的胰腺癌好,临床上应将其与其他胰腺肿瘤加以区别。     

胰腺导管内乳头状黏液性肿瘤研究进展

胰腺导管内乳头状黏液性肿瘤(pancreatic intraepithelial neoplasias,IPMNs)是新近被认识的一种胰腺囊性肿瘤.在不同类型胰腺肿瘤中,IPMNs预后相对较好,具有与一般胰腺肿瘤不同的分子及临床病理特征:按照乳头状结构及黏蛋白的表达又可将其分为多个亚型,不同亚型又具有不同的病理特点.病理学家提出IPMNs是胰腺癌发生过程中的重要阶段,深入研究IPMNs及其不同亚型的病理特点及其所蕴含的分子变化,将能更好的揭示IPMNs的发病机制及生物学特征.本文回顾相关文献,从分子特征、病理特征、诊断治疗及预后判断等不同角度对目前IPMNs的研究进展作一综述.     

胰腺导管内乳头状黏液性肿瘤患者K-ras基因的突变

目的探讨K-ras基因在胰腺导管内乳头状黏液性肿瘤(IPMN)组织中的突变情况。方法采用荧光定量PCR法检测31例IPMN组织内K-ras基因突变情况,分析突变与临床特征的关系。结果 31例样本共检测10例(32.26%)发生K-ras基因突变,其中胰胆管型突变率5例、胃型2例、肠型2例、嗜酸细胞型1例,各临床分型差异显著(P0.05)。浸润型突变率(85.7%)明显高于非浸润型(16.7%,P0.01);不同分化类型差异有统计学意义(P0.001)。结论 IPMN存在K-ras基因突变,突变与IPMN分型、分化及浸润有关。     

胰腺导管内乳头状黏液瘤的研究进展

胰腺导管内乳头状黏液瘤(intraductal papillary mucinous neoplasm,IPMNs)为来源于胰腺导管上皮的分化程度多样的胰腺肿瘤,位于主胰管或其分支内,可分泌黏液,为胰腺癌的癌前病变.区分IPMNs的良恶性对制定治疗方案,预估患者预后意义重大.随影像学和内镜的发展,IPMNs发现率逐年提...     

内镜下光动力治疗胰腺导管内乳头状黏液性肿瘤2例

胰腺导管内乳头状黏液性肿瘤是一种以导管扩张、导管内乳头状生长和黏液分泌为特征的肿瘤,具有一定的恶变潜能。内镜下光动力治疗是一种腔内局部治疗肿瘤的新技术,可使肿瘤组织坏死、脱落,达到局部杀灭肿瘤的作用。本文报道了2例内镜下光动力治疗该病的病例,总体疗效满意。     

不同病理类型的胰腺导管内乳头状黏液性肿瘤的临床特征

目的 总结不同病理类型胰腺导管内黏液性乳头状瘤(IPMT)的临床表现,提高对IPMT的诊治水平.方法 回顾分析1996年3月至2008年9月间经手术切除且病理证实的49例IPMT患者的临床表现、影像学特点及病理学特征,比较分析良性、交界性、恶性IPMT的临床表现.结果 49例IPMT患者中男27例,女22例,平均年龄(58±11)岁.良性19例,交界性9例,恶性21例.3类IPMT患者在性别、发病年龄、烟酒史、胰腺炎发作史、糖尿病病史,是否存在腹痛、腰背部放射痛、腹胀、腹泻、消瘦等症状,血CEA、AST、ALT水平,肿瘤位置及肿瘤分型上的差异均无明显统计学意义.但黄疸、术前CA19-9和碱性磷酸酶水平、肿瘤直径、主胰管直径、囊性肿瘤内是否存在隔膜、附壁结节的大小等方面的差异有统计学意义.恶性IPMT术后5年有1例病死,1例复发;交界性和良性IPMT有1例复发,1例因其他疾病病死.结论 不同病理类型的IPMT 临床特征存在一些差异,需综合判断进行鉴别.     

Predictive factors associated with malignancy of intraductal papillary mucinous pancreatic neoplasms

AIM:To identify preoperative predictive factors associated with malignancy of intraductal papillary mucinous neoplasms(IPMNs) of the pancreas.METHODS:Between April 1995 and April 2010,129 patients underwent surgical resection for IPMNs at our institute and had confirmed pathologic diagnoses.The medical records were retrospectively reviewed and immunohistochemical staining for mucin(MUC) in pancreatic tissues was performed.RESULTS:Univariate analysis showed that the following five variables were closely asso...     

Helicobacter pylori is undetectable in intraductal papillary mucinous neoplasm

BackgroundAbout half of the world population is infected with Helicobacter pylori (H. pylori), a bacterium associated with gastric cancer and considered to be a risk factor for pancreatic ductal adenocarcinoma. Whether the bacterium is associated with intraductal papillary mucinous neoplasm, believed to be a precursor of pancreatic ductal adenocarcinoma, is unknown. The aim of this study was to investigate the presence of H. pylori DNA in tissue sections of intraductal papillary mucinous neoplasm.MethodsThe presence of H. pylori DNA was tested in a retrospective controlled study of formalin-fixed, paraffin-embedded pancreatic tissues from 24 patients who underwent surgery for intraductal papillary mucinous neoplasm. Histologically normal tissues surrounding neoplasms were used as control. H. pylori DNA was evaluated after deparaffinization, DNA extraction, and purification, and results were evaluated statistically.ResultsSamples were collected from 13 males and 11 females with mean age 59 years (range 44–77), and consisted of 19 cases of main-duct and three cases of branched-duct intraductal papillary mucinous neoplasm. Two patients were diagnosed with pancreatic cancer and main-duct intraductal papillary mucinous neoplasm. H. pylori DNA was not detected either in intraductal papillary mucinous neoplasm tissue, or in surrounding normal tissue.ConclusionsAlthough H. pylori has been implicated in pancreatic ductal adenocarcinoma, it may not play a key role in the development of intraductal papillary mucinous neoplasm.     

Imaging features of intraductal papillary mucinous neoplasms of the pancreas in multi-detector row computed tomography

AIM： To retrospectively evaluate the imaging features of pancreatic intraductal papillary mucinous neoplasms （IPMNs） in multi-detector row computed tomography （MDCT）.
METHODS： A total of 20 patients with pathologicallyconfirmed intraductal papillary mucinous neoplasms （IPMNs） were included in this study. Axial MDCT images combined with CT angiography （CTA） and multiplanar volume reformations （MPVR） or curved reformations （CR） were preoperatively acquired. Two radiologists （Tan L and Wang DB） reviewed all the images in consensus using an interactive picture archiving and communication system. The disputes in readings were resolved through consultation with a third experienced radiologist （Chen KM）. Finally, the findings and diagnoses were compared with the pathologic results.
RESULTS： The pathological study revealed 12 malignant IPMNs and eight benign IPMNs. The diameters of the cystic lesions and main pancreatic ducts （MPDs） were significantly larger in malignant IPMNs compared with those of the benign IPMNs （P 〈 0.05）. The combinedtype IPMNs had a higher rate of malignancy than the other two types of IPMNs （P 〈 0.05）. Tumors with mural nodules and thick septa had a significantly higher incidence of malignancy than tumors without these features （P 〈 0.05）. Communication of side-branch IPMNs with the MPD was present in nine cases at pathologic examination. Seven of them were identified from CTA and MPVR or CR images. From comparison with the pathological diagnosis, the sensitivity, specificity, and accuracy of MDCT in characterizing the malignancy of IPMN of the pancreas were determined to be 100%, 87.5% and 95%, respectively.
CONCLUSION： MDCT with CTA and MPVR or CR techniques can elucidate the imaging features of IPMNs and help predict the malignancy of these tumors.     

Multifocal intraductal papillary mucinous neoplasm of the pancreas-A case report

Cystic neoplasms of the pancreas are relatively rare, comprising 10 percent of pancreatic cysts and only 1 percent of pancreatic cancers. Cystic neoplasms include mucinous cystic neoplasms, serous cystadenomas, papillary cystic tumors, cystic islet cell tumors and intraductal papillary mucinous neoplasms of the pancreas （IPMNs）. IPMN was first described in 1982. It has been most commonly described in 60 to 70 years old males, and represents a relatively ＂new＂ but increasingly recognized disease. The improvement and widespread use of modern imaging equipments and heightened awareness of physicians contribute to the increasing incidence of IPMN. The majority of IPMNs are located in the pancreatic head （75%） while the rest involves the body/tail regions. Multifocal IPMNs have been hypothesized, but the true presence of multifocality is unknown. Here we present a 72-year- old male diagnosed with IPMN （carcinoma in situ） in the pancreatic head and a branch duct type IPMN （duct atypia） in the pancreatic body and tail. The patient underwent a Whipple intervention and a distal pancreatectomy. A three-year disease-free survival has been observed so far.     

Endoscopic ultrasound in the diagnosis of pancreatic intraductal papillary mucinous neoplasms

Pancreatic cystic lesions are increasingly recognised due to the widespread use of different imaging modalities.Intraductal papillary mucinous neoplasms(IPMNs)of the pancreas represent a common,but also heterogeneous group of cystic tumors with a significant malignant potential.These neoplasms must be differentiated from other cystic tumors and properly classified into their different types,main-duct IPMNs vs branchduct IPMNs.These types have a different malignant potential and therefore,different treatment strategies need to be implemented.Endoscopic ultrasound(EUS)offers the highest resolution of the pancreas and can aid in the differential diagnosis,classification and differentiation between benign and malignant tumors.The addition of EUS fine-needle aspiration can supply further information by obtaining fluid for cytology,measurement of tumor markers and perhaps DNA analysis.Novel techniques,such as the use of contrast and sophisticated equipment,like intraductal probes can provide information regarding malignant features and extent of these neoplasms.Thus,EUS is a valuable tool in the diagnosis and appropriate management of these tumors.     

Endoscopic ultrasonography findings of pancreatic parenchyma for predicting subtypes of intraductal papillary mucinous neoplasms

Background and aimsThe subtypes of intraductal papillary mucinous neoplasms (IPMNs) are closely associated with the clinicopathological behavior and recurrence after surgical resection. However, there are no established non-invasive methods to confirm the subtypes of IPMNs without surgery. The aim of this study is to predict the subtypes of IPMNs using the findings of endoscopic ultrasonography (EUS).MethodsSixty-two consecutive patients with IPMNs who underwent EUS before surgery were retrospectively reviewed. The following EUS findings were analyzed and their relationship with the subtypes was evaluated: diameter of the main pancreatic duct, cyst size, number of cysts, height of mural nodule, early chronic pancreatitis (CP) finding, fatty parenchyma and atrophic parenchyma.ResultsThe subtypes of IPMNs were as follows: gastric (G)-type 38 (61%), intestinal (I) -type 14 (23%) and pancreatobiliary (PB) -type 10 (16%). Fatty parenchyma was significantly associated with G-type (P < 0.0001). Early CP findings ≥2 and atrophic parenchyma were significantly correlated with I-type (P < 0.0001). PB-type was significantly associated with pancreatic parenchyma without early CP findings or fatty degeneration in comparison to the other subtypes (P < 0.0001). Using the above characteristic EUS findings, the sensitivity, specificity, and accuracy were as follows: 63%, 92% and 74%, respectively, in G-type, 57%, 96% and 87% in I-type, and 90%, 94% and 94% in PB-type.ConclusionsThe evaluation of EUS findings, especially focused on the pancreatic parenchyma, has the potential to predict the subtypes of IPMN.     

Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma

Background/objectivesResections for intraductal papillary mucinous neoplasm (IPMN) have increased last decades. Overall survival (OS) for conventional pancreatic ductal adenocarcinoma (PDAC) is well known but OS for invasive IPMN (inv-IPMN) is not as conclusive. This study aims to elucidate potential differences in clinicopathology and OS between these tumor types and to investigate if the raised number of resections have affected outcome.MethodsConsecutive patients ≥18 years of age resected for inv-IPMN and PDAC at Karolinska University Hospital between 2009 and 2018 were included. Clinicopathological variables were analyzed in multivariable regression models. Outcome was assessed calculating two-year OS, estimating OS using the Kaplan-Meier model and comparing survival functions with log-rank test.Results513 patients were included, 122 with inv-IPMN and 391 with PDAC. During the study period both the proportion resected inv-IPMN and two-year OS, irrespective of tumor type, increased (2.5%–45%; p < 0.001 and 44%–57%; p = 0.005 respectively). In Kaplan-Meier survival analysis inv-IPMN had more favorable median OS (mOS) compared to PDAC (33.6 months vs 19.3 months, p = 0.001). However, in multivariable Cox Regression analysis, tumor type was not a predictor for death, but so were resection period, tumor subtype and N-stage (all p < 0.001).ConclusionIn this large single center observational cohort study, inv-IPMN seemed to have favorable survival outcome compared to PDAC, but after adjusting for predictors for death this benefit vanished. The combination of a pronounced increase in resected inv-IPMN and a concurrent hazard abatement for death within 2 years during the study period proved to be a principal factor.